Financing proceeds will be used to complete product development and conduct clinical trials in the U.S. for tools to perform minimally invasive surgeries through the mouth and into the peritoneal cavity.

— From the report of an equity investment in start-up firm Apollo Endosurgery, concerning a new approach to surgery, “Apollo in ‘A’ $11.5 million round; Simplex Diabetic garners $50 M,” pp. 1, 8.